|
1
|
Hirata K, Egawa S, Kimura Y, et al:
Current status of surgery for pancreatic cancer. Dig Surg.
24:137–147. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Satake K, Kanazawa G, Kho I, Chung YS and
Umeyama K: A clinical evaluation of carbohydrate antigen 19-9 and
carcinoembryonic antigen in patients with pancreatic carcinoma. J
Surg Oncol. 29:15–21. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dillhoff M, Liu J, Frankel W, Croce C and
Bloomston M: MicroRNA-21 is overexpressed in pancreatic cancer and
a potential predictor of survival. J Gastrointest Surg.
12:2171–2176. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bloomston M, Frankel WL, Petrocca F, et
al: MicroRNA expression patterns to differentiate pancreatic
adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA.
297:1901–1908. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Habbe N, Koorstra JB, Mendell JT, et al:
MicroRNA miR-155 is a biomarker of early pancreatic neoplasia.
Cancer Biol Ther. 8:340–346. 2009. View Article : Google Scholar :
|
|
9
|
Ryu JK, Hong SM, Karikari CA, Hruban RH,
Goggins MG and Maitra A: Aberrant microRNA-155 expression is an
early event in the multistep progression of pancreatic
adenocarcinoma. Pancreatology. 10:66–73. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Y, Vandenboom TG II, Wang Z, Kong D,
Ali S, Philip PA and Sarkar FH: miR-146a suppresses invasion of
pancreatic cancer cells. Cancer Res. 70:1486–1495. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Y, Li M, Wang H, Fisher WE, Lin PH,
Yao Q and Chen C: Profiling of 95 microRNAs in pancreatic cancer
cell lines and surgical specimens by real-time PCR analysis. World
J Surg. 33:698–709. 2009. View Article : Google Scholar
|
|
12
|
Yu J, Li A, Hong SM, Hruban RH and Goggins
M: MicroRNA alterations of pancreatic intraepithelial neoplasias.
Clin Cancer Res. 18:981–992. 2012. View Article : Google Scholar :
|
|
13
|
Kent OA, Mullendore M, Wentzel EA, et al:
A resource for analysis of microRNA expression and function in
pancreatic ductal adenocarcinoma cells. Cancer Biol Ther.
8:2013–2024. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li A, Omura N, Hong SM, et al: Pancreatic
cancers epigenetically silence SIP1 and hypomethylate and
overexpress miR-200a/200b in association with elevated circulating
miR-200a and miR-200b levels. Cancer Res. 70:5226–5237. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu J, Ohuchida K, Mizumoto K, et al:
MicroRNA, hsa-miR-200c, is an independent prognostic factor in
pancreatic cancer and its upregulation inhibits pancreatic cancer
invasion but increases cell proliferation. Mol Cancer. 9:1692010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee EJ, Gusev Y, Jiang J, et al:
Expression profiling identifies microRNA signature in pancreatic
cancer. Int J Cancer. 120:1046–1054. 2007. View Article : Google Scholar
|
|
17
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen X, Ba Y, Ma L, et al:
Characterization of microRNAs in serum: a novel class of biomarkers
for diagnosis of cancer and other diseases. Cell Res. 18:997–1006.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of posttranscriptional regulation by
microRNAs: are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mitchell PS, Parkin RK, Kroh EM, et al:
Circulating microRNAs as stable blood-based markers for cancer
detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hasselmann DO, Rappl G, Tilgen W and
Reinhold U: Extracellular tyrosinase mRNA within apoptotic bodies
is protected from degradation in human serum. Clin Chem.
47:1488–1489. 2001.PubMed/NCBI
|
|
22
|
Cocucci E, Racchetti G and Meldolesi J:
Shedding microvesicles: artefacts no more. Trends Cell Biol.
19:43–51. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kosaka N, Iguchi H, Yoshioka Y, Takeshita
F, Matsuki Y and Ochiya T: Secretory mechanisms and intercellular
transfer of microRNAs in living cells. J Biol Chem.
285:17442–17452. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Arroyo JD, Chevillet JR, Kroh EM, et al:
Argonaute2 complexes carry a population of circulating microRNAs
independent of vesicles in human plasma. Proc Natl Acad Sci USA.
108:5003–5008. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vickers KC, Palmisano BT, Shoucri BM,
Shamburek RD and Remaley AT: MicroRNAs are transported in plasma
and delivered to recipient cells by high-density lipoproteins. Nat
Cell Biol. 13:423–433. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang J, Chen J, Chang P, et al: MicroRNAs
in plasma of pancreatic ductal adenocarcinoma patients as novel
blood-based biomarkers of disease. Cancer Prev Res (Phila).
2:807–813. 2009. View Article : Google Scholar
|
|
27
|
Morimura R, Komatsu S, Ichikawa D, et al:
Novel diagnostic value of circulating miR-18a in plasma of patients
with pancreatic cancer. Br J Cancer. 105:1733–1740. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ho AS, Huang X, Cao H, Christman-Skieller
C, Bennewith K, Le QT and Koong AC: Circulating miR-210 as a novel
hypoxia marker in pancreatic cancer. Transl Oncol. 3:109–113. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kawaguchi T, Komatsu S, Ichikawa D, et al:
Clinical impact of circulating miR-221 in plasma of patients with
pancreatic cancer. Br J Cancer. 108:361–369. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Moriyama T, Ohuchida K, Mizumoto K, et al:
MicroRNA-21 modulates biological functions of pancreatic cancer
cells including theirproliferation, invasion, and chemoresistance.
Mol Cancer Ther. 8:1067–1074. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Giovannetti E, Funel N, Peters GJ, et al:
MicroRNA-21 in pancreatic cancer: correlation with clinical outcome
and pharmacologic aspects underlying its role in the modulation of
gemcitabine activity. Cancer Res. 70:4528–4538. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hwang JH, Voortman J, Giovannetti E, et
al: Identification of microRNA-21 as a biomarker for
chemoresistance and clinical outcome following adjuvant therapy in
resectable pancreatic cancer. PLoS One. 5:e106302010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kadera BE, Li L, Toste PA, Wu N, Adams C,
Dawson DW and Donahue TR: MicroRNA-21 in pancreatic ductal
adenocarcinoma tumor-associated fibroblasts promotes metastasis.
PLoS One. 8:e719782013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu R, Chen X, Du Y, et al: Serum miRNA
expression profile as a biomarker in the diagnosis and prognosis of
pancreatic cancer. Clin Chem. 58:610–618. 2012. View Article : Google Scholar
|
|
35
|
Ali S, Almhanna K, Chen W, Philip PA and
Sarkar FH: Differentially expressed miRNAs in the plasma may
provide a molecular signature for aggressive pancreatic cancer. Am
J Transl Res. 28:28–47. 2010.
|
|
36
|
Liu J, Gao J, Du Y, et al: Combination of
plasma microRNAs with serum CA19-9 for early detection of
pancreatic cancer. Int J Cancer. 131:683–691. 2012. View Article : Google Scholar
|
|
37
|
Kong X, Du Y, Wang G, et al: Detection of
differentially expressed microRNAs in serum of pancreatic ductal
adenocarcinoma patients: miR-196a could be a potential marker for
poor prognosis. Dig Dis Sci. 56:602–609. 2011. View Article : Google Scholar
|
|
38
|
Hamada S, Satoh K, Fujibuchi W, et al:
MiR-126 acts as a tumor suppressor in pancreatic cancer cells via
the regulation of ADAM9. Mol Cancer Res. 10:3–10. 2012. View Article : Google Scholar
|
|
39
|
Hamada S, Satoh K, Miura S, et al: MiR-197
induces epithelial-mesenchymal transition in pancreatic cancer
cells by targeting p120 catenin. J Cell Physiol. 228:1255–1263.
2013. View Article : Google Scholar
|
|
40
|
Veronese A, Lupini L, Consiqlio J, et al:
Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res.
70:3140–3149. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Guled M, Lahti L, Lindholm PM, Salmenkivi
K, Bagwan I, Nicholson AG and Knuutila S: CDKN2A, NF2, and JUN are
dysregulated among other genes by miRNAs in malignant
mesothelioma-A miRNA microarray analysis. Genes Chromosomes Cancer.
48:615–623. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hao J, Zhang S, Zhou Y, Hu X and Shao C:
MicroRNA 483-3p suppresses the expression of DPC4/Smad4 in
pancreatic cancer. FEBS Lett. 585:207–213. 2011. View Article : Google Scholar
|
|
43
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Cassification of Malignant Tumours. 7th edition.
Wiley-Blackwell; New York, NY: 2009
|
|
44
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liang Y, Ridzon D, Wong L and Chen C:
Characterization of microRNA expression profiles in normal human
tissues. BMC Genomics. 8:1662007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wilentz RE, Iacobuzio-Donahue CA, Argani
P, et al: Loss of expression of Dpc4 in pancreatic intraepithelial
neoplasia: evidence that DPC4 inactivation occurs late in
neoplastic progression. Cancer Res. 60:2002–2006. 2000.PubMed/NCBI
|
|
47
|
Biankin AV1, Biankin SA, Kench JG, et al:
Aberrant p16 (INK4A) and DPC4/Smad4 expression in intraductal
papillary mucinous tumours of the pancreas is associated with
invasive ductal adenocarcinoma. Gut. 50:861–868. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yamaguchi K1, Ohuchida J, Ohtsuka T,
Nakano K and Tanaka M: Intraductal papillary-mucinous tumor of the
pancreas concomitant with ductal carcinoma of the pancreas.
Pancreatology. 2:484–490. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Uehara H, Nakaizumi A, Ishikawa O, et al:
Development of ductal carcinoma of the pancreas during follow-up of
branch duct intraductal papillary mucinous neoplasm of the
pancreas. Gut. 57:1561–1565. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Tanno S, Nakano Y, Koizumi K, et al:
Pancreatic ductal adenocarcinomas in long-term follow-up patients
with branch duct intraductal papillary mucinous neoplasms.
Pancreas. 39:36–40. 2010. View Article : Google Scholar
|
|
51
|
Ingkakul T1, Sadakari Y, Ienaga J, Satoh
N, Takahata S and Tanaka M: Predictors of the presence of
concomitant invasive ductal carcinoma in intraductal papillary
mucinous neoplasm of the pancreas. Ann Surg. 25:70–75. 2010.
View Article : Google Scholar
|
|
52
|
Kanno A, Satoh K, Hirota M, et al:
Prediction of invasive carcinoma in branch type intraductal
pappilary mucinous neoplasms of the pancreas. J Gastroenterol.
45:952–959. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Li A1, Yu J, Kim H, Wolfgang CL, Canto MI,
Hruban RH and Goggins M: MicroRNA array analysis finds elevated
serum miR-1290 accurately distinguishes patients with low-stage
pancreatic cancer from healthy and disease controls. Clin Cancer
Res. 19:3600–3610. 2013. View Article : Google Scholar : PubMed/NCBI
|
